Business
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2025.
About this update from Ideaya Biosciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"130 required PFS events confirmed by BICR in the Phase 2/3 OptimUM-02 trial of darovasertib and crizotinib combination in 1L HLA*A2-negative metastatic uveal melanoma (mUM); topline results expected by approximately the last week of March","length":243,"tagName":"p"}]},{"val":[{"type":"text","content":"Darovasertib is anticipated to be in three randomized, Phase 3 registrational trials in uveal melanoma, including the metastatic, neoadjuvant and adjuvant settings, by H1 '26","length":183,"tagName":"p"}]},{"val":[{"type":"text","content":"Initiation of IDE849 (DLL3 TOP1 ADC) monotherapy registrational study in the second line/refractory setting (2L+) of small cell lung cancer (SCLC) and/or neuroendocrine carcinomas (NEC) targeted by the end of 2026","length":218,"tagName":"p"}]},{"val":[{"type":"text","content":"Preliminary clinical data update from IDEAYA-sponsored global Phase 1 trial of IDE849 expected by the end of 2026","length":118,"tagName":"p"}]},{"val":[{"type":"text","content":"~$1.05 billion of cash, cash equivalents, and marketable securities as of December 31, 2025; expected to fund operations into 2030","length":130,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":892,"olType":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, provided a business update and announced financial results for the fourth quarter and full year ended December 31, 2025.","length":272,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/IDEAYA Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/IDEAYA Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":255,"url":"https://media.zenfs.com/en/prnewswire.com/49d79e447894ee1780aa7326a51b46ad"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/uOi9OWeA5cY_B4txoQR9PA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ0OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/49d79e447894ee1780aa7326a51b46ad","width":400,"height":255}},"href":"https://mma.prnewswire.com/media/820568/IDEAYA_v1_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""We had a strong quarter of clinical execution, clinical pipeline expansi...